A test that provides cancer risk for all

	lyriad
QOI	netics
501	

Myriad Genetic Laboratories, Inc. 320 Wakara Way - Salt Lake City, Utah 84108 PH: +1 (877) 283-6709 - FX: +1 (801) 883-8998 www.myriad.com **Outside U.S.A** Email: CustomerSupport@myriadgenetics.eu

Affix one	bar	code	label	here	

Test Request Form

Patient

✓ To avoid delays please complete entire form

Please print all information in BLOCK LETTERS

Specimen collection date (required): (DD-MMM-YYYY)	Specimen collected by (required)

MyRisk[™]

Hereditary Cancer Test

Ordering physician

Date of birth (DD-MMM-YYYY):	Last name:	Degree:	
Sex assigned at birth: Female Male Patient ID:	First name:	Clinical ID:	
Legal name (Last):	Institution:		
Legal name (First):	Street, nr:		
Billing information	City, postal code:	Day phone:	
Payor ID:	Country:	Fax:	
or research #:	E-mail:		
voucher #:			

Send results to (Optional - additional clinician can be listed to receive status updates and the patient's copy of the results)

Last name:	First name:	Institution:	
Street, nr:	City, postal code:	Country:	E-mail:

Test requested

☐ Myriad myRisk™ Hereditary Cancer*				
□ Myriad myRisk [™] Hereditary Cancer* Update Test (available to patients previously tested negative with BRACAnalysis®, COLARIS®, and/or COLARIS AP®)				
Accession number from previous Myriad report				
BRACAnalysis® - HBOC criteria				
☐ Multisite 3 BRACAnalysis® - For patients of Ashkenazi Jewish ancestry ☐ Reflex to BRACAnalysis® if the Multisite 3 is negative				
□ Colaris® - Lynch criteria				
Colaris AP® (Familial Polyposis syndrome criteria)				
 Single Site Testing (for family of known mutation carriers) Specify Gene: and Mutation: Relationship: My Patient is the: (e.g., maternal aunt) of the known mutation carrier. Required: Include a copy of the known mutation carrier's report. 				
Other Test:				
*The genes associated with MyRisk [™] Hereditary Cancer Panel are subject to change. To view the full list of genes available on the MyRisk [™] panel, please visit: www.myriad.com/gene-table				
Risk analysis options (tick to exclude from report):				
Do not include RiskScore®				
Do not include RiskScore® or Tyrer-Cuzick				

Ancestry (Select all that apply)

🗆 Ashkenazi Jewish	🗆 Black / African	□ Middle Eastern	🗆 Pacific Islander	
🗆 Asia		o 🛛 Native American		🗆 White / Non-Hispanic

A test that provides cancer risk for all

Age at



□ No personal history of cancer

Patient has been diagnosed with:

Test Request Form

To avoid delays please complete entire form

Please print all information in BLOCK LETTERS

Patient personal history of cancer and other clinical information (Select all that apply)

Patient is currently

Fatient has been u	lagnoseu with:	diagnosis	being treated	Pathology / Other mile		
Breast cancer	□ Left □ Right			Ductal invasive Lobular invasive DCIS Metastatic Bilateral Premenopausal Triple negative (ER-, PR-, HER2-)		
Endometrial / Uterine cancer				Tumor MSI-High or IHC Abnormal - Result Tumor not available for MSI-High or IHC Abnormal testing		
Ovarian cancer				□ Non-epithelial		
Prostate cancer				Gleason Score		
□ Colon / Rectal ca	ncer			Type: Mucinous Signet ring Medullary growth pattern Tumor infiltrating lymphocytes Crohn's-like lymphocytic reaction Patient's tumor is MSI-High or IHC abnormal - Result		
Colon / Rectal ad	Colon / Rectal adenomas Color / Rectal adenomas Color / Rectal adenomatous Polyposis (FAP) Cumulative Adenomatous Polyp #: 1 1 2-5 6-9 10-19 20-99		□ Known Familial Adenomatous Polyposis (FAP) Cumulative Adenomatous Polyp #: □1 □2-5 □6-9 □10-19 □20-99 □100+			
🗆 Hematologic cano	cer					
Other cancer(s) (e.g. cancers of the ston kidney, ureter, brain, ski	nach, pancreas, bile duct, n and others)			Туре:		
		% on one of the Lynch Syndrome Risk Models (PREMM ₅ , MMRpro, or MMRpredict)		sk Models (PREMM ₅ , MMRpro, or MMRpredict)		
			Bone Marrow transplant recipient Type: Autologous Allogeneic (if allogeneic please contact helpmed@myriadgenetics.eu)			
Check if applicable to patient:		Blood transfusion recipient within 28 days of sample collection Type: 🗆 Whole blood 🔅 Packed red blood cells				

Pathology / Other Info

Family history of cancer

No known family history of cancer				
Relationship to patient	Maternal (mother's side)	Paternal (father's side)	Cancer site	Age at each diagnosis

Blood transfusion recipient within 12 months of sample collection Date: (DD-MMM-YYYY)

The MyRisk Plus Management Tool and RiskScore™ may not be reported without an accurate and specific personal and family history included.

Breast cancer risk model information

Height (cm):	Weight (kg):	Information about patient's female relatives:	Other information:
Age at time of first menstrual period:			Mammographic density:
Is patient	1enopausal	Number of daughters:	Has the patient had her breast density assessed? \Box No \Box Yes
currently: Post-menopausal Age of p	oost-menopausal onset		If yes, complete one of the following for the most recent assessment:
Has this patient had No a live birth? Yes: patient's age at first child birth:		Number of sisters:	□ Volpara® volumetric density:%
			□ VAS percentage density:%
Has patient ever used hormone replacement therapy? No Yes If yes, treatment type: Combined Estrogen only Progesterone only If yes, is patient a: Current user: Started years ago		Number of maternal aunts	□ BI-RADS [®] ATLAS density (Select one of the following):
		(mother's sisters):	Almost entirely fatty
			□ Scattered fibroglandular density □ Extremely dense □ Unknown
Intended use for		Number of paternal aunts	NOTE: Risk associated with mammographic density is not incorporated into
Past user: Stopped	years ago	(father's sisters):	RiskScore (v.1), nor Tyrer-Cuzick (v.7) calculations provided on the clinical report.

Please indicate if the patient has had a breast biopsy showing one or more of the following results: \Box N/A (No biopsy or none of the listed results) \Box Hyperplasia \Box Atypical hyperplasia \Box LCIS \Box Biopsy with unknown or pending results

Authorized signature (Physician / healthcare provider)

I hereby authorize testing and confirm that informed consent has been obtained from the patient for blood or saliva to be sent to Myriad for analysis. I confirm that this test is medically necessary and results will be used in the medical management and treatment decisions for the patient. I hereby declare that the clinical information described on this Test Request Form is correct and belongs to the patient mentioned above. I hereby attest that the person listed in the ordering physician space above is authorized by law in the relevant jurisdiction to order the test requested herein. Date (DD-MMM-YYYY)

Ordering physician / healthcare provider's signature	if a different date is not provided above)
Internal use only: Bill Institution BIE	If previous genetic testing of one of the requested genes has been performed on this patient or a family member, the ordering physician or health care provider should inform the laboratory within two (2) business days of sending the specimen.

Information

Sex assigned at birth is a label given to an individual at birth, typically "male" or "female".

A legal name identifies a person for legal and administrative purposes. It is recorded on a birth certificate, marriage certificate, or other government issued document that records a name change.

For information or questions regarding Myriad's privacy policy, please visit our website: http://www.myriadgenetics.eu

